CAMLINFINE — Camlin Fine Sciences Balance Sheet
0.000.00%
- IN₹31.29bn
- IN₹37.69bn
- IN₹16.13bn
- 57
- 15
- 100
- 62
Annual balance sheet for Camlin Fine Sciences, fiscal year end - March 31st, INR millions except per share, conversion factor applied.
2020 March 31st | 2021 March 31st | 2022 March 31st | 2023 March 31st | 2024 March 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IAS | IAS | IAS | IAS | IAS |
Status: | Final | Final | Final | Final | Final |
Cash | |||||
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 539 | 1,231 | 1,288 | 952 | 812 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 2,892 | 3,040 | 3,537 | 3,937 | 3,656 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 6,750 | 7,947 | 8,935 | 10,878 | 10,007 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 4,132 | 5,367 | 7,403 | 8,344 | 8,023 |
Net Goodwill | |||||
Net Intangible Assets | |||||
Long Term Investments | |||||
Long Term Notes Receivable | |||||
Other Long Term Assets | |||||
Total Assets | 12,341 | 14,816 | 18,001 | 20,601 | 19,517 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 5,478 | 4,776 | 5,953 | 7,930 | 7,323 |
Long Term Debt | |||||
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Deferred Income Tax | |||||
Minority Interest | |||||
Total Other Liabilities | |||||
Total Funded Status | |||||
Total Liabilities | 8,309 | 8,382 | 10,521 | 12,407 | 10,870 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Unrealized Gain / Loss | |||||
Other Equity | |||||
Total Equity | 4,031 | 6,434 | 7,479 | 8,194 | 8,648 |
Total Liabilities & Shareholders' Equity | 12,341 | 14,816 | 18,001 | 20,601 | 19,517 |
Total Common Shares Outstanding |